MicroPort Scientific (HKG:0853) expects its continuing operations to record a net loss of no more than $50 million for the first half of 2026, widening from a net loss of $49 million a year earlier, according to a Wednesday Hong Kong bourse filing.
The company said the loss was primarily due to the finance costs of about US$43 million incurred during the period.
Revenue from continuing operations is expected to grow 12% to 14% year over year, while overseas business revenue is expected to increase about 140%.
The interim results are expected to be published by the end of August.
Shares of the medical device company were down nearly 2% in recent trade.